|
Papilloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Although some individuals with HRAS p.Gly13Asp developed papillomata and vascular proliferation lesions, no malignant tumors occurred, similar to what was reported for individuals harboring the HRAS p.Gly13Cys.
|
28371260 |
2017 |
|
Papilloma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Male-to-male transmission of Costello syndrome: G12S HRAS germline mutation inherited from a father with somatic mosaicism.
|
19206176 |
2009 |
|
Papilloma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Severe neonatal manifestations of Costello syndrome.
|
18039947 |
2008 |
|
Papilloma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome.
|
17054105 |
2007 |
|
Papilloma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation.
|
16329078 |
2006 |
|
Papilloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Although MGMT promoter methylation was not generally correlated with ras mutations, the frequency of MGMT methylation was higher in MNNG-initiated, mezerein-promoted papillomas with mutations in Ha-ras compared to papillomas with Ki-ras.
|
16094607 |
2006 |
|
Papilloma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy.
|
16372351 |
2006 |
|
Papilloma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Somatic mosaicism for an HRAS mutation causes Costello syndrome.
|
16969868 |
2006 |
|
Papilloma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases.
|
16443854 |
2006 |
|
Papilloma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Recurring HRAS mutation G12S in Dutch patients with Costello syndrome.
|
16881968 |
2006 |
|
Papilloma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Germline mutations in HRAS proto-oncogene cause Costello syndrome.
|
16170316 |
2005 |
|
Papilloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
K14/IL-1 alpha mice crossed with the highly sensitive TG.AC mice, constitutively expressing mutant Ha-Ras, also failed to develop papillomas or carcinomas.
|
12759452 |
2003 |
|
Papilloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Papillomas were examined for mutations in the c-Ha-ras proto-oncogene.
|
11765016 |
2001 |
|
Papilloma
|
0.500 |
Biomarker
|
disease |
LHGDN |
The Tg.AC (v-Ha-ras) transgenic mouse model provides a reporter phenotype of skin papillomas in response to either genotoxic or nongenotoxic carcinogens.
|
11695562 |
2001 |
|
Papilloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The Tg.AC (v-Ha-ras) transgenic mouse model provides a reporter phenotype of skin papillomas in response to either genotoxic or nongenotoxic carcinogens.
|
11695562 |
2001 |
|
Papilloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We have utilized an in vitro correlate of squamous cell carcinogenesis, in which progression stages from normal squamous epithelium to dysplastic lesions and to SCC are represented by primary cultures of normal keratinocytes, by human papilloma virus-immortalized keratinocytes (UP) and by HPVimmortalized/v-Ha-ras transfected tumorigenic keratinocytes (UPR).
|
10783309 |
2000 |
|
Papilloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Using a transgenic mouse model expressing the E2F1 gene under the control of a keratin 5 (K5) promoter, we previously demonstrated that increased E2F1 activity can promote tumorigenesis by cooperating with either a v-Ha-ras transgene to induce benign skin papillomas or p53 deficiency to induce spontaneous skin carcinomas.
|
10454586 |
1999 |
|
Papilloma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Analysis of HK1.fos/alpha papillomas and carcinomas revealed that the endogenous c-Ha-ras gene possessed mutations at codons 12, 13, and 61 at the papilloma stage, but no mutations of the p53 tumor suppressor gene were detected.
|
10569807 |
1999 |
|
Papilloma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Characteristic codon 61 mutations in the Ha-ras gene were found in most of the papillomas and SCCs induced by DMBA and TPA in transgenic as well as nontransgenic mice.
|
9115586 |
1997 |
|
Papilloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
PEG-3 expression is elevated in rodent cells displaying a progressed-transformed phenotype and in rodent cells transformed by various oncogenes, including Ha-ras, v-src, mutant type 5 adenovirus (Ad5), and human papilloma virus type 18.
|
9256446 |
1997 |
|
Papilloma
|
0.500 |
Biomarker
|
disease |
CTD_human |
Chemically induced skin carcinogenesis in a transgenic mouse line (TG.AC) carrying a v-Ha-ras gene.
|
8330346 |
1993 |
|
Papilloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The amplification of myc oncogene was found in 14/57 lesions, 13 of which showed both myc and ras gene amplification. c-myc and/or c-Ha-ras DNA was more frequently amplified in cutaneous squamous cell carcinomas (8/14 cases) and anogenital papillomas (4/6 cases), than in common and plantar warts (3/14 cases) or actinic keratoses (2/10 cases).HPV DNA was detected in 26/57 biopsies.
|
1317208 |
1992 |
|
Papilloma
|
0.500 |
Biomarker
|
disease |
BEFREE |
From these results, it is suggested that somatic mutational activation of the human c-Ha-ras transgene plays a causative role in the occurrence of forestomach and skin papillomas induced by MNU administration in these transgenic mice.
|
1737360 |
1992 |
|
Papilloma
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|